**This article has been corrected:** During the assembly of [Figure 3E](#F1){ref-type="fig"} and [3F](#F1){ref-type="fig"}, the western blot of pCHK1-p317 in [Figure 3F](#F1){ref-type="fig"} was inadvertently used for pRPA-p4/8 in [Figure 3E](#F1){ref-type="fig"}. The corrected [Figure 3](#F1){ref-type="fig"} is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.
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![Effect of miR146a on FANCD2 monoubiquitination and the FA pathway.\
(**A** and **B**) HeLa cells were transfected with miR146a in the absence or presence of anti-miR146a (**A**) or miR146a-insensitive FANCM cDNA (**B**). After a 48h transfection, the cells were treated with 5mM HU for 5 h. The protein levels of FANCM and FANCD2 were measured by western blotting. Monoubiquitinated FANCD2 is indicated as the upper band of doublet protein bands corresponding to FANCD2. (**C** and **D**) After HeLa cells underwent the same treatment as **A** and **B**, cells were analyzed for FANCD2 foci formation. DAPI was used for nuclear staining. Results are shown as the mean ± SD (n = 3); ^\*\*^ *P* \< 0.01. (**E** and **F**) Indicated cells were treated with 5mM HU for 5 hr. Cell lysates were analyzed by Western blotting with antibodies against pCHK1-S317, CHK1, pRPA-S4/8, and RPA.](oncotarget-11-2024-g001){#F1}
